Bioventus Study Shows Novel Placental Tissue Biologic Candidate Inhibited Inflammatory and Catabolic Responses In Vitro

Rhea-AI Summary

Bioventus Inc. (Nasdaq: BVS) announced that its human placental tissue product, PTP-001, significantly reduced pain and cartilage degeneration in a rat osteoarthritis model during a six-week study. Findings published in Osteoarthritis and Cartilage revealed that PTP-001's efficacy matched corticosteroid treatment. The company sees PTP-001 as a promising candidate for managing osteoarthritis symptoms and potentially modifying the disease. Further research and development plans are in place for PTP-001, aimed at addressing unmet clinical needs.

Positive

• PTP-001 showed significant pain reduction in a rat osteoarthritis model.
• Efficacy of PTP-001 comparable to corticosteroid treatment.
• Potential for PTP-001 to address unmet clinical needs in osteoarthritis.

Negative

• None.

Demonstrated Significant Reduction of Pain and Cartilage Degeneration in Rat Osteoarthritis Model

DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced human placental tissue, prepared as a particulate composition, termed PTP-001, was shown to contain an array of beneficial growth factors, cytokines and anti-inflammatory molecules, which significantly reduced pain and cartilage degeneration in a rat osteoarthritis (OA) model. These findings were published on May 19, 2021 in Osteoarthritis and Cartilage available at https://www.oarsijournal.com/article/S1063-4584(21)00734-2/fulltext.

The in vivo activity of PTP‐001 on joint pain and histopathology was evaluated in a rat model of OA that was induced surgically by destabilization of the medial meniscus. In the model, PTP‐001 significantly reduced pain responses throughout six weeks post‐dosing as compared to a saline treatment. The magnitude and duration of pain reduction following a single intra-articular treatment with PTP‐001 was comparable to that observed for animals treated with a corticosteroid (active control). For rats that received two doses of PTP‐001, administered two weeks apart, significant reductions in cartilage degeneration scores were also observed.

“We believe that PTP‐001 represents a promising biologic candidate for osteoarthritis, with a multi‐modal potential mechanism of action that may contribute to symptom management and disease modification,” said Carl Flannery Senior Director, Scientific Affairs, Bioventus. “We will continue with further research and development of PTP‐001, as we believe it represents a novel approach for the treatment of OA, and potentially other musculoskeletal conditions with unmet clinical need.”

Authors of this study include: Carl R. Flannery, Ph.D., Bioventus; Scott A. Seaman, Ph.D., Bioventus; Kelly E. Buddin B.S., Bioventus; Michael A. Nasert, B.A., MTF Biologics; Eric J. Semler, Ph.D., MTF Biologics; Kathryn L. Kelley, B.S.; University of North Carolina, Chapel Hill; Marc Long, Ph.D., MTF Biologics; Jacob Favret, B.S., Bolder BioPATH; Alessandra Pavesio, M.S., Bioventus; and Richard F. Loeser, M.D., University of North Carolina, Chapel Hill.

About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment & joint preservation, restorative therapies and bone graft substitutes.. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter.

Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning the expected benefits, clinical development and market opportunities of PTP-001. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release include, but are not limited to, statements about the adverse impacts on our business as a result of the COVID-19 pandemic; our dependence on a limited number of products; our ability to develop, acquire and commercialize new products, line extensions or expanded indications; the continued and future acceptance of our existing portfolio of products and any new products, line extensions or expanded indications by physicians, patients, third-party payers and others in the medical community; our ability to differentiate the hyaluronic acid (“HA”) viscosupplementation therapies we own or distribute from alternative therapies for the treatment of osteoarthritic; the proposed down-classification of non-invasive bone growth stimulators, including our Exogen system, by the U.S. Food and Drug Administration (“FDA”); our ability to achieve and maintain adequate levels of coverage and/or reimbursement for our products, the procedures using our products, or any future products we may seek to commercialize; our ability to complete acquisitions or successfully integrate new businesses, products or technologies in a cost-effective and non-disruptive manner; competition against other companies; the negative impact on our ability to market our HA products due to the reclassification of HA products from medical devices to drugs in the United States by the FDA; our ability to attract, retain and motivate our senior management and qualified personnel; our ability to continue to research, develop and manufacture our products if our facilities are damaged or become inoperable; failure to comply with the extensive government regulations related to our products and operations; enforcement actions if we engage in improper claims submission practices or in improper marketing or promotion of our products; the FDA regulatory process and our ability to obtain and maintain required regulatory clearances and approvals; failure to comply with the government regulations that apply to our human cells, tissues and cellular or tissue-based products; the clinical studies of any of our future products that do not product results necessary to support regulatory clearance or approval in the United States or elsewhere; and the other risks identified in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission (“SEC”), including Bioventus’ Annual Report on Form 10-K for the period ended December 31, 2020, as such factors may be updated from time to time in Bioventus’ other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Bioventus’ website at ir.bioventus.com. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business.

Media Contact:
Thomas Hill
919-474-6715
thomas.hill@bioventus.com 

Investor Inquiries:
Mike Piccinino, CFA, IRC
Westwicke/ICR
investor.relations@bioventus.com 

FAQ

What is PTP-001 and its significance for Bioventus (BVS)?

PTP-001 is a human placental tissue product that has shown significant pain reduction and cartilage preservation in animal tests, positioning it as a promising candidate for osteoarthritis treatment.

When were the findings about PTP-001 published?

The findings were published on May 19, 2021, in the journal Osteoarthritis and Cartilage.

What animal model was used to test PTP-001?

A rat model of osteoarthritis was used to evaluate the effectiveness of PTP-001.

How does PTP-001 compare to traditional treatments for osteoarthritis?

PTP-001's pain reduction was found to be comparable to that of corticosteroid treatments in the study.

What are the future plans for PTP-001 by Bioventus (BVS)?

Bioventus plans to continue research and development of PTP-001 to explore its potential for osteoarthritis and other musculoskeletal conditions.